Evaluation of trimethoprim-sulphamethoxazole compound in treatment of salmonella infections.
Fifty patients suffering from infections caused by various salmonella species were treated with trimethoprim-sulphamethoxazole compound. Twenty-three had enteric fever and two were biliary carriers of Salmonella typhi. The other 25 suffered from infections caused by salmonella species other than S. typhi or S. paratyphi B. Twenty-one of the patients with enteric fever responded clinically to the drug, one failed treatment, and one died. Two patients suffering from typhoid fever relapsed and three temporarily excreted S. typhi in stools following treatment. One of the typhoid carriers was successfully treated. All patients with infections caused by salmonella species other than S. typhi or S. paratyphi B responded to treatment but 17 continued to excrete the organism in their stools after the course of trimethoprim-sulphamethoxazole compound. Four patients developed rashes during therapy and two became anaemic.
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000139:chemically induced; D002648:Child; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D005493:Folic Acid Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012480:Salmonella Infections / Q000188:drug therapy*; D012482:Salmonella paratyphi A; D012486:Salmonella typhimurium; D013420:Sulfamethoxazole / Q000008:administration & dosage* / Q000009:adverse effects; D014435:Typhoid Fever / Q000188:drug therapy
D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013420:Sulfamethoxazole